Vaxil Bio

Vaxil Bio is an immunotherapy biotechnology company developing a novel drug discovery and development platform based on signal peptides to address infectious diseases and cancer. Its lead product ImMucin has completed a Phase I/II trial for multiple myeloma, and the pipeline includes vaccines and treatments for tuberculosis and COVID-19. The company collaborates with medical research centers and government and military research programs to evaluate peptide vaccines and related therapies, including partnerships with Tel Aviv Sourasky Medical Center and testing programs with the U.S. Army Medical Research Institute of Infectious Diseases. Founded in 2006, Vaxil Bio focuses on advancing immuno-oncology and infectious disease candidates through its signal peptide approach.